Use of Drug-Eluting Stents as a Function of Predicted Benefit Clinical and Economic Implications of Current Practice

被引:50
作者
Amin, Amit P. [1 ]
Spertus, John A. [2 ,3 ]
Cohen, David J. [2 ,3 ]
Chhatriwalla, Adnan [2 ,3 ]
Kennedy, Kevin F. [2 ,3 ]
Vilain, Katherine [2 ,3 ]
Salisbury, Adam C. [2 ,3 ]
Venkitachalam, Lahshmi
Lai, Sue Min [4 ]
Mauri, Laura [5 ]
Normand, Sharon-Lise T. [7 ,8 ]
Rumsfeld, John S. [9 ,10 ]
Messenger, John C. [9 ]
Yeh, Robert W. [6 ]
机构
[1] Washington Univ, Sch Med, Dept Med, Cardiovasc Div,Barnes Jewish Hosp, St Louis, MO 63110 USA
[2] St Lukes Mid Amer Heart & Vasc Inst, Kansas City, MO USA
[3] Univ Missouri, Kansas City, MO USA
[4] Univ Kansas, Med Ctr, Dept Prevent Med, Kansas City, MO USA
[5] Harvard Univ, Brigham & Womens Hosp, Dept Med, Div Cardiol, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA USA
[7] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
[8] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA
[9] Univ Colorado, Div Cardiol, Sch Med, Aurora, CO USA
[10] Denver Vet Affairs Med Ctr, Denver, CO USA
关键词
PERCUTANEOUS CORONARY INTERVENTION; BARE-METAL STENTS; POISSON REGRESSION APPROACH; MYOCARDIAL-INFARCTION; COST-EFFECTIVENESS; AMERICAN-COLLEGE; OUTCOMES; MULTICENTER; SAFETY; DISCONTINUATION;
D O I
10.1001/archinternmed.2012.3093
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Benefits of drug-eluting sterns (DES) in percutaneous coronary intervention (PCI) are greatest in those at the highest risk of target-vessel revascularization (TVR). Drug-eluting stents cost more than bare-metal stents (BMS) and necessitate prolonged dual antiplatelet therapy (DAPT), which increases costs, bleeding risk, and risk of complications if DAPT is prematurely discontinued. Our objective was to assess whether DES are preferentially used in patients with higher predicted TVR risk and to estimate if lower use of DES in low-TVR-risk patients would be more cost-effective than the existing DES use pattern. Methods: We analyzed more than 1.5 million PCI procedures in the National Cardiovascular Data Registry (NCDR) CathPCI registry from 2004 through 2010 and estimated 1-year TVR risk with BMS using a validated model. We examined the association between TVR risk and DES use and the cost-effectiveness of lower DES use in low-TVR-risk patients (50% less DES use among patients with <10% TVR risk) compared with existing DES use. Results: There was marked variation in physicians' use of DES (range 2%-100%). Use of DES was high across all predicted TVR risk categories (73.9% in TVR risk <10%; 78.0% in TVR risk 10%-20%; and 83.2% in TVR risk >20%), with a modest relationship between TVR risk and DES use (relative risk, 1.005 per 1% increase in TVR risk [95% CI, 1.005-1.006]). Reducing DES use by 50% in low-TVR-risk patients was projected to lower US health care costs by $205 million per year while increasing the overall TVR event rate by 0.5% (95% Cl, 0.49%-0.51%) in absolute terms. Conclusions: Use of DES in the United States varies widely among physicians, with only a modest correlation to patients' risk of restenosis. Less DES use among patients with low risk of restenosis has the potential for significant cost savings for the US health care system while minimally increasing restenosis events.
引用
收藏
页码:1145 / 1152
页数:8
相关论文
共 34 条
  • [1] ACC/AHA 2007 guide lines for the management of patients with unstable Angina/Non-ST-Elevation myocardial infraction - Executive summary
    Anderson, Jeffrey L.
    Adams, Cynthia D.
    Antman, Elliott M.
    Bridges, Charles R.
    Califf, Robert M.
    Casey, Donald E., Jr.
    Chavey, William E., II
    Fesmire, Francis M.
    Hochman, Judith S.
    Levin, Thomas N.
    Lincoff, A. Michael
    Peterson, Eric D.
    Theroux, Pierre
    Wenger, Nanette Kass
    Wright, R. Scott
    Smith, Sidney C., Jr.
    Jacobs, Alice K.
    Adams, Cynthia D.
    Riegel, Barbara
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (07) : 652 - 726
  • [2] 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
    Anderson, Jeffrey L.
    Adams, Cynthia D.
    Antman, Elliott M.
    Bridges, Charles R.
    Califf, Robert M.
    Casey, Donald E., Jr.
    Chavey, William E., II
    Fesmire, Francis M.
    Hochman, Judith S.
    Levin, Thomas N.
    Lincoff, A. Michael
    Peterson, Eric D.
    Theroux, Pierre
    Wenger, Nanette Kass
    Wright, R. Scott
    Ettinger, Steven M.
    Ganiats, Theodore G.
    Jneid, Hani
    Philippides, George J.
    Zidar, James Patrick
    Jacobs, Alice K.
    Albert, Nancy
    Hochman, Judith S.
    Creager, Mark A.
    Kushner, Frederick G.
    Ohman, Erik Magnus
    Guyton, Robert A.
    Stevenson, William G.
    Halperin, Jonathan L.
    Yancy, Clyde W.
    [J]. CIRCULATION, 2011, 123 (18) : E426 - E579
  • [3] Bertrand OF, 2008, J INVASIVE CARDIOL, V20, P99
  • [4] Stent thrombosis late after implantation of first-generation drug-eluting stents - A cause for concern
    Camenzind, Edoardo
    Steg, P. Gabriel
    Wijns, William
    [J]. CIRCULATION, 2007, 115 (11) : 1440 - 1455
  • [5] Cost-effectiveness of drug-eluting stents: if only all things were equal
    Chew, DPB
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2005, 182 (08) : 376 - 377
  • [6] Department of Health Care Policy Harvard Medical School, MASSDAC ONL RISK CAL
  • [7] Drug-eluting stents - The price is not right
    Eisenberg, Mark J.
    [J]. CIRCULATION, 2006, 114 (16) : 1745 - 1754
  • [8] Groeneveld Peter W, 2007, J Interv Cardiol, V20, P1, DOI 10.1111/j.1540-8183.2007.00214.x
  • [9] The Impact of New Cardiovascular Device Technology on Health Care Costs
    Groeneveld, Peter W.
    Polsky, Daniel
    Yang, Feifei
    Yang, Lin
    Epstein, Andrew J.
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2011, 171 (14) : 1289 - 1291
  • [10] Temporal Trends in the Use of Drug-eluting Stents for Approved and Off-label Indications: A Longitudinal Analysis of a Large Multicenter Percutaneous Coronary Intervention Registry
    Gualano, Sarah K.
    Gurm, Hitinder S.
    Share, David
    Smith, Dean
    Aronow, Herbert D.
    LaLonde, Thomas
    Bates, Eric R.
    Changezi, Hameem
    McNamara, Richard
    Moscucci, Mauro
    [J]. CLINICAL CARDIOLOGY, 2010, 33 (02) : 111 - 116